With EAN going virtual this year, the global SARS-CoV2 pandemic was never far from the attendees’ minds. After a brief overview of the putative mechanisms for SARS-CoV2 accessing the brain,…
read moreAlzheimer’s disease (AD) is a very common malady of the elderly, currently affecting 5.8 million Americans above the age of 65. It accounts for 60–80% of all dementia cases, which…
read moreWhile researchers are looking at the potential of stem cells in the treatment of multiple sclerosis (MS), novel, promising immune-modulating therapies are being developed. At this year’s virtual EAN Congress,…
read moreData suggest that between 2 and 5% of patients with multiple sclerosis (MS) are under 18 years old,1 yet there is only one approved treatment option in this population.2,3 During…
read moreWhy do some glioblastoma patients live longer than others? Alice Laurenge (Institut du Cerveau et de la Moelle épinière, Sorbonne Université and Hôspitaux universitaire La Pitié Salpêtrière – Charles Foix,…
read moreWhile most patients with epilepsy respond to one or two drugs, it is estimated that 30% develop drug resistance.1 At EAN 2020, Sylvain Rheims (Department of Functional Neurology and Epileptology,…
read more